German Biotech Company LenioBio Receives EUR 3.7M Of EU4Health Funding

The funding will support the further development of LenioBio’s cell-free protein expression platform, ALiCE®, as a fast, on-demand manufacturing technology for medicines. The project aligns with the mission of the European Commission’s Health Emergency Preparedness and Response Authority (HERA) and runs from July 1, 2025, through late 2027.

LenioBio will use the €3.7M EU4Health grant to scale its platform and advance its application in medicine manufacturing through a project titled “Innovative protein medicine biomanufacturing with Continuous-Modular ALiCE.”

The project focuses on three key areas: scaling up ALiCE® lysate production by improving yields, increasing batch sizes, and shifting to continuous manufacturing; enhancing ALiCE® for targeted protein medicines like vaccines, multispecific antibodies, and growth factors through new functionalities and scalable modular production methods; and preparing for GMP-grade lysate production by establishing quality systems, analytical standards, and regulatory documentation.

Read Also - Banyan Software Acquires Netherlands-based Company Presspage

This initiative supports the EU’s broader goal of making essential medicines more accessible, affordable, and sustainably produced.

“This grant is another significant milestone for LenioBio. It enables us to scale our platform and broadens its application for medicine production, providing a future proof solution for the agile production of novel and complex proteins.” said André Goerke, CEO of LenioBio.

LenioBio GmbH, led by CEO André Goerke, is a German biotech company focused on advancing next-generation protein expression technology. Founded in September 2016, the company operates from its headquarters in Düsseldorf, with R&D and production facilities in Aachen.

Its core platform, ALiCE®—a cell-free protein expression system—enables rapid and scalable production of complex proteins without using living cells. Already applied in vaccine development and drug discovery, ALiCE® is now being further developed with EU4Health support to meet clinical and large-scale manufacturing needs.

About LenioBio

LenioBio GmbH is a biotech company specializing in protein expression technologies that enable the discovery, development, and large-scale production of proteins without the limitations of living cells. Founded in September 2016, the company is based in Düsseldorf, Germany, with dedicated R&D and production laboratories located in Aachen.